Dulaglutide

FDA label

Read the full label on DailyMed ↗

Titration Increase dose after at least 4 weeks on current dosage

Renal No adjustment needed (including ESRD)

Hepatic Use with caution (limited experience)

Once weekly; day of administration may be changed if last dose was ≥3 days prior

Instructions

• Inject SC in abdomen, thigh, or upper arm; rotate sites
• Any time of day, with or without food
• If a dose is missed and ≥3 days remain until the next dose, take it as soon as possible

Contraindications

• Personal or family history of medullary thyroid carcinoma, or MEN 2

Cautions

• Acute pancreatitis
• Hypoglycemia with insulin secretagogues or insulin
• Hypersensitivity reactions (anaphylaxis, angioedema)
• Acute kidney injury from volume depletion
• Severe GI reactions; not recommended in severe gastroparesis
• Diabetic retinopathy complications
• Acute gallbladder disease
• Pulmonary aspiration during general anesthesia/deep sedation

Adverse reactions

• Nausea
• Diarrhea
• Vomiting
• Abdominal pain
• Decreased appetite

Pregnancy Use only if potential benefit justifies risk; animal studies showed fetal harm.

Lactation No data; consider developmental/health benefits of breastfeeding vs risk.